Kurser indlæses...
Prognose
Vi har ingen analytikerdata for denne virksomhed.
Diskussioner i communityet
Der er endnu ingen diskussion om dette aktiv.
Start diskussionNyheder Til nyhedsfeedet
Hikma Pharmaceuticals appoints Tobias Hestler as independent non-executive board member
Hikma Pharmaceuticals has appointed Tobias Hestler, with effect from Thursday, as an independent, non-executive member of the board. Hestler will join the audit, remuneration and nomination and governance committees and is due to take over as chair of the audit committee after the 2027 annual general meeting, succeeding Douglas Hurt. Hestler was most recently Group CFO and Executive Director at Haleon and previously held senior finance roles at GSK and Novartis; he currently sits on the boards of Convatec and Alliance Pharma and is treasurer of the Elton John AIDS Foundation. » Mere på de.investing.com
Hikma Pharmaceuticals approves £0.62 dividend for 2025
Hikma Pharmaceuticals paid a dividend of £0.62 per share for the 2025 financial year; the total payout amounts to £140.38 million, 2.50% above the previous year. The ex-dividend date was 24 April 2026, and the dividend yield for 2025 is 4.03%. Over three years the share price in London fell by 23.94%, but total return (price plus dividends) rose by 31.97%. FactSet analysts expect a dividend of $0.85 per share for 2026, which would lift the yield to about 4.69%. » Mere på finanzen.net
Hikma confirms 2026 outlook after solid Q1
Hikma has confirmed its 2026 outlook after a first quarter that went as expected. The injectables division is targeting low single-digit revenue growth with an adjusted operating margin of 27–28%, driven by strong US demand for Tyzavan. The US-Rx division also progressed as planned, supported by the launch of a generic tapentadol; expansion projects in Bedford and Columbus are advancing. The company is exiting the 503b compounding business, has repurchased £54.8m of shares up to 17 April, and is monitoring the geopolitical situation in the Middle East while sales remain robust but it faces cost-driven inflationary pressure. » Mere på de.investing.com
Hikma starts $250 million share buyback programme
Hikma has launched a share buyback programme to acquire up to $250 million of ordinary shares. The programme runs until no later than 23 September 2026 and is split into two equal tranches of up to $125 million each, to be executed first by Citigroup (until 9 June 2026) and then by J.P. Morgan. Repurchases are based on the shareholder authorisation granted on 24 April 2025 for up to 22,188,645 ordinary shares; acquired shares will be cancelled or held as treasury stock, with the aim of reducing capital. » Mere på de.investing.com
Brookfield confirms no takeover bid for Hikma Pharmaceuticals
Brookfield Private Capital (DIFC) Limited said it does not intend to make an offer for Hikma Pharmaceuticals despite recent speculation. The statement cites Rule 2.8 of the UK City Code, which temporarily restricts Brookfield from making further offers unless certain circumstances arise (for example, the Hikma board gives consent or another company announces a firm offer). The announcement ends the current takeover speculation; Hikma is listed on the London Stock Exchange and is a multinational pharmaceutical company. » Mere på de.investing.com
Historisk udbytte Udbytte
Alle nøgletal for udbytte Alle nøgletalVirksomhedstal
| (EUR) | juni 2026 | YoY |
|---|---|---|
| Omsætning | 1,5 mia. | - |
| Bruttofortjeneste | 632,65 mio. | - |
| Nettoresultat | 193,79 mio. | - |
| EBITDA | 418,87 mio. | - |
Fundamentale data
| Nøgletal | Værdi |
|---|---|
Markedsværdi | 4,16 mia. € |
Antal aktier | 207,02 mio. |
Højeste/laveste i 52 uger | 21,15 € - 14,25 € |
Udbytteafkast | 3,68 % |
Udbytte TTM | 0,75 € |
Beta | 0,62 |
P/E (PE Ratio) | 12,34 |
PEG (PEG Ratio) | -0,13 |
K/I (PB Ratio) | 1,84 |
P/S (PS Ratio) | 1,34 |
Virksomhedsprofil
Hikma Pharmaceuticals PLC udvikler, fremstiller, markedsfører og sælger en række generiske, brandede og in-licenserede farmaceutiske produkter. Virksomheden tilbyder sine produkter i faste, halvfaste, flydende og injicerbare endelige doseringsformer. Den opererer gennem tre segmenter: Injectables, Generics og Branded. Injectables-segmentet leverer generiske injicerbare produkter, primært til brug på hospitaler. Generics-segmentet tilbyder orale og andre ikke-injicerbare generiske produkter til detailmarkedet. Branded-segmentet tilbyder brandede generiske produkter og in-licenserede produkter til detail- og hospitalsmarkederne. Virksomheden leverer sine produkter inden for forskellige terapeutiske områder, herunder antiinfektiva, kardiovaskulære midler, centralnervesystemet, diabetes, onkologi, smertebehandling og respiratoriske midler. Den opererer i Storbritannien, USA, Mellemøsten, Nordafrika, Europa og internationalt. Virksomheden blev grundlagt i 1978 og har hovedkontor i London, Storbritannien.
| Navn | Hikma Pharmaceuticals |
| CEO | Said Samih Taleb Darwazah |
| Hjemsted | London,
gl Storbritannien |
| Websted | |
| Sektor | Sundhed |
| Branche | Lægemidler |
| Børsnotering | 01.11.2005 |
| Medarbejdere | 9.500 |
Tickersymboler
| Børs | Symbol |
|---|---|
London Stock Exchange | HIK.L |
Pnk | HKMPF |
Frankfurt | H5P.F |
Düsseldorf | H5P.DU |
London | HIK.L |
München | H5P.MU |